Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position

NEXT STORY
Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
PREV STORY
Press release Biocartis Group NV: BIOCARTIS MEETS 2021 KEY OBJECTIVES
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and Development of mRNA-based Vaccines and Biotherapies

author_avatar
NASDAQ Market News

CytomX Announces First Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., May 05, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

author_avatar
NASDAQ Market News

First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma

author_avatar
NASDAQ Market News